Eric Shroff Sells 709 Shares of Abbott Laboratories (NYSE:ABT) Stock

Abbott Laboratories (NYSE:ABT) SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded down $0.57 during trading hours on Tuesday, reaching $113.55. The stock had a trading volume of 6,686,129 shares, compared to its average volume of 9,201,159. The firm has a 50-day moving average of $116.90 and a 200-day moving average of $125.00. The firm has a market cap of $197.31 billion, a price-to-earnings ratio of 30.52, a PEG ratio of 1.82 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently modified their holdings of the business. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Abound Financial LLC acquired a new position in Abbott Laboratories during the fourth quarter worth about $26,000. Finally, Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at about $27,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA cleared Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader intended to improve patient convenience and clinical workflow. The approval, together with existing reimbursement for implantable PA sensors, could boost physician adoption and revenue potential in Abbott’s cardiac portfolio. Abbott wins FDA approval for updated heart failure monitoring device How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Analyst commentary highlights reasons to like Abbott’s durable device franchises and margin profile but reiterates skepticism after the recent softer quarter that contributed to underperformance versus the S&P over the past six months. This keeps sentiment mixed until revenue and growth re‑acceleration are clearer. 2 Reasons to Like ABT and 1 to Stay Skeptical
• Negative Sentiment: Clustered insider selling: multiple senior executives sold a combined ~3,055 shares on March 2 at about $115.58 per share (notable filings from VP John McCoy, EVPs Mary Moreland, Daniel Salvadori, Elizabeth Cushman and SVP Eric Shroff). While the executives retain large holdings, concentrated sales can pressure sentiment near the sale price. SEC Form 4 (John A. Jr. McCoy)
• Negative Sentiment: Market reaction/price momentum — coverage and market notes report ABT shares have recently pulled back (near the mid‑$110s) after the quarter, which is reinforcing selling pressure in the near term. Investors are watching upcoming catalysts and whether CardioMEMS adoption lifts growth enough to reverse the trend. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why Abbott (ABT) Stock Sinks As Market Gains: Here’s Why (Zacks)

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of research reports. BTIG Research reduced their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Daiwa Securities Group cut their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.